Biosimilars market seen reaching $48.52 billion by 2030
The Business Research Company says the global biosimilars market will grow from $21.85 billion in 2025 to $25.53 billion in 2026, then nearly double to $48.52 billion by 2030. The report points to patent expirations, higher healthcare spending and broader use in cancer and autoimmune treatment as key drivers.
Why it matters: - Biosimilars offer lower-cost alternatives to expensive biologic drugs, which can reduce pressure on patients, providers and health systems. - The market’s expected growth signals broader adoption of biologic therapies at a time when healthcare spending continues to rise.
What happened: - The Business Research Company published a biosimilars market analysis covering market size, trends and forecasts through 2035. - The report estimates the biosimilars market will rise from $21.85 billion in 2025 to $25.53 billion in 2026. - The report projects the market will reach $48.52 billion by 2030. - North America was the leading biosimilars region in 2025. - The Middle East is projected to be the fastest-growing region during the forecast period.
The details: - The report pegs 2025-2026 growth at a 16.9% compound annual growth rate. - Forecast growth from 2026 to 2030 is estimated at a 17.4% CAGR. - Historical growth has been driven by higher rates of chronic and autoimmune disease, the high cost of originator biologics, demand for cost-efficient therapies, advances in biopharmaceutical R&D and stronger healthcare infrastructure in emerging markets. - Future growth is expected to come from patent expirations on major biologic drugs, expanded use in cancer and autoimmune disorders, supportive government policies, manufacturing expansion in Asia-Pacific and strategic collaborations between biopharma companies and contract manufacturers. - The report highlights personalized biosimilar development, cost-efficient biologics production, regulatory alignment, expansion in developing markets and stronger partnerships as key trends. - Biosimilars are derived from living organisms and can differ slightly in composition because of their complex molecular size and structure. - Biosimilars are different from generic drugs, which are chemically identical copies of small-molecule medicines. - Rising healthcare spending is a major catalyst for the category. - England’s total health spending reached £182 billion ($196.78 billion) in 2022/23, according to the Health Foundation. - Planned spending in England is projected to rise to £192 billion ($207.59 billion) in 2024/25, with inflation limiting real growth to about 0.6% versus 2023/24. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also added market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables to its 2026 reports. - More information is available in the full report and a free sample report.
Between the lines: - The forecast suggests biosimilars are moving from a niche substitute to a more established part of mainstream treatment pathways. - Patent expirations and manufacturing scale-up point to a more competitive market, which could further pressure pricing. - Regional growth outside North America suggests demand is broadening as access and health-system budgets evolve.
What's next: - The market is expected to keep expanding through 2030 as more biologics lose exclusivity and biosimilar adoption widens. - The report points to more collaboration between manufacturers and contract development and manufacturing organizations as a likely next phase. - Continued policy support and regulatory alignment will likely shape how quickly biosimilars gain share in key markets.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Middle East Political Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.